Jasmine's questions to Apellis Pharmaceuticals Inc (APLS) leadership • Q2 2025
Question
Jasmine, on behalf of Eliana Merle at UBS, asked about the potential impact of a competitor's donation to co-pay foundations on Apellis's free drug usage and inquired about the latest compliance and adherence rates for Cyfovri.
Answer
CEO Dr. Cedric Francois reiterated that foundation funding is independent of Apellis. CMO Dr. Caroline Baumal stated that real-world data from large physician groups indicates Cyfovri compliance is around 80%, driven by motivated patients seeking to treat their persistent vision loss.